• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Small Molecule PET Tracer Penetrates Brain But Lacks Specificity

by
November 8, 2026
in Chemistry, Health
Reading Time: 5 mins read
0
Small Molecule PET Tracer Penetrates Brain But Lacks Specificity

Small Molecule PET Tracer Penetrates Brain But Lacks Specificity

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Published in EJNMMI Radiopharmacy and Chemistry, the study introduces [11C]Methyl-V-0219, a carbon-11 labeled analogue of V-0219, a known GLP-1R positive allosteric modulator. The primary objective of this work was to develop a blood-brain barrier (BBB)-penetrating tracer to address the limitations of current peptide-based PET agents, which exhibit poor central nervous system penetration due to their size and hydrophilicity. The findings demonstrate that while the new tracer successfully crosses the blood-brain barrier, it lacks the in vivo specificity required for accurate receptor imaging in living subjects.

The development of [11C]Methyl-V-0219 was driven by the clinical importance of GLP-1R in the treatment of obesity and type 2 diabetes. Although GLP-1R agonists are widely used therapeutics, the distribution of these receptors in the brain, particularly in areas regulating appetite and satiety, remains difficult to visualize. Existing PET tracers based on the exendin-4 peptide, such as [68Ga]Ga-DO3A-Exendin-4, are effective for imaging peripheral and pancreatic GLP-1R but are too large to cross the intact blood-brain barrier. Consequently, they cannot image GLP-1R expression in most brain regions, limiting their utility for understanding central metabolic regulation. V-0219, a small molecule allosteric modulator, was selected as a scaffold because its physicochemical properties are more compatible with BBB penetration than those of exendin-based peptides.

The synthesis of [11C]Methyl-V-0219 employed a palladium-catalyzed Suzuki–Miyaura coupling reaction, a strategy that allows for the direct incorporation of carbon-11 into a carbon framework. This method is particularly useful for labeling aryl or alkenyl carbon skeletons, which cannot be easily labeled using conventional heteroatom methylation. The reaction utilized [11C]methyl iodide, generated from cyclotron-produced [11C]CO2, and a pinacol boronic ester precursor. The synthesis was performed in a custom-built tracer production system and completed in less than 30 minutes, a timeframe compatible with the 20.4-minute half-life of carbon-11. The process was optimized using both tetrahydrofuran and dimethylformamide solvent systems, with water added to facilitate the hydrolysis of the boronate ester precursor and improve coupling efficiency.

The radiochemical yield of the synthesis was 36 ± 18% (n = 16), with a radiochemical purity of 98.6 ± 1.6% (n = 16). After purification by preparative HPLC and reformulation, the tracer was obtained in a phosphate-buffered saline solution containing approximately 10% ethanol. The non-decay-corrected activity yields reached up to 4.9 GBq, with a mean of 3.3 ± 1.2 GBq (n = 11). The high molar activity and radiochemical purity made the compound suitable for subsequent in vitro and in vivo biological evaluations. Stability assays in human plasma confirmed that the tracer remained intact, with 94.7 ± 0.1% of the parent compound present after 30 minutes of incubation at 37 °C.

In vitro autoradiography experiments demonstrated that [11C]Methyl-V-0219 binds to tissues expressing human and rodent GLP-1R. Pre-incubation with unlabeled V-0219 or Methyl-V-0219 significantly reduced tracer binding, indicating that the interaction is displaceable and specific to the receptor in these cell models. However, the study also revealed that the tracer exhibits cross-reactivity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptors. This lack of selectivity is notable, as GIP and GCG receptors are partially homologous to GLP-1R, but the degree of cross-reactivity observed in this study had not been previously reported for the parent compound V-0219.

In vivo PET imaging was conducted in both rats and pigs to assess the biodistribution and brain kinetics of [11C]Methyl-V-0219. The results showed rapid uptake of the tracer in the brain, with standardized uptake value (SUV) values exceeding 2 within the first 5 minutes post-injection. This rapid entry into the brain confirms that the molecule successfully penetrates the blood-brain barrier, a key requirement for central GLP-1R imaging. However, the brain uptake was followed by a progressive washout, with SUV values dropping below 1 by the end of the 60-minute acquisition. This kinetic profile suggests that while the tracer can enter the brain, it does not remain bound to the receptor for a sufficient duration to generate a clear imaging signal.

When compared with the established GLP-1R tracer [68Ga]Ga-DO3A-Exendin-4, [11C]Methyl-V-0219 showed a distinct biodistribution pattern. In pigs, [68Ga]Ga-DO3A-Exendin-4 demonstrated pronounced retention in the pituitary gland and pancreas, tissues known for high GLP-1R expression. In contrast, [11C]Methyl-V-0219 did not exhibit noticeable retention in these GLP-1R-rich tissues. Instead, the new tracer showed high hepatic retention and increasing activity in the intestines, consistent with hepatobiliary clearance. This pattern is typical for lipophilic compounds, which are often excreted via the liver and bile. The absence of pancreatic retention is particularly significant, as the pancreas has high GLP-1R expression and is readily accessible to peptide-based tracers.

Blocking and competition studies in rats further elucidated the lack of in vivo specificity. Pre-blocking with unlabeled Methyl-V-0219 or competition with the same compound administered after tracer injection did not alter the brain uptake or kinetic profile of [11C]Methyl-V-0219. The time-activity curves remained comparable across all conditions, indicating that the observed brain signal was not driven by specific, displaceable binding to GLP-1R. Instead, the signal likely reflects non-specific uptake and perfusion. This discrepancy between the in vitro binding results and the in vivo imaging outcomes highlights the challenges of translating receptor binding affinity from cell models to complex physiological environments. The in vitro experiments used receptor-overexpressing cell lines, which may not accurately reflect the lower receptor density and competitive environment of the brain in vivo.

The accumulation of [11C]Methyl-V-0219 in glandular tissues, such as the harderian and salivary glands, was also observed in both rats and pigs. This uptake is likely due to the lipophilic nature of the tracer and its passive diffusion into lipid-rich tissues, rather than receptor-mediated binding. This biodistribution profile limits the utility of [11C]Methyl-V-0219 for quantitative imaging of GLP-1R in the brain, as the non-specific background signal is too high to distinguish specific receptor binding.

The study concludes that while the radiosynthesis of [11C]Methyl-V-0219 is feasible and robust, the compound does not meet the criteria for a specific GLP-1R PET tracer. The lack of in vivo specificity, combined with the rapid brain washout and prominent peripheral clearance, indicates that the current scaffold is not suitable for clinical or preclinical imaging of central GLP-1R. However, the work provides valuable insights into the requirements for developing small molecule PET tracers for incretin receptors. The findings suggest that future designs must focus on improving receptor selectivity and in vivo retention, potentially by modifying the physicochemical properties of the molecule to reduce lipophilicity and off-target binding. This study serves as a foundation for the rational design of next-generation tracers that can effectively image GLP-1R in the brain.

Subject of Research: Preclinical evaluation of a small molecule PET tracer for brain GLP-1R imaging

Article Title: Radiosynthesis and preclinical evaluation of [11C]Methyl-V-0219, a small molecule glucagon-like peptide-1 allosteric modulator for PET brain imaging

Article References: Lechi, F., Khalil, A., Bautista, P. N., Öberg, J., Balestri, L. J. I., Eriksson, O., Eriksson, J., & Odell, L. R. (2026). Radiosynthesis and preclinical evaluation of [11C]Methyl-V-0219, a small molecule glucagon-like peptide-1 allosteric modulator for PET brain imaging. EJNMMI Radiopharmacy and Chemistry, 11(1), Article 58. https://doi.org/10.1186/s41181-026-00486-4

Image Credits: AI Generated

DOI: 10.1186/s41181-026-00486-4

Keywords: PET imaging, GLP-1R, radiosynthesis, blood-brain barrier, carbon-11, Suzuki-Miyaura coupling, preclinical study, metabolic disorders, allosteric modulator, biodistribution, preclinical, evaluation

News Source: Cassandra Pierce. (November 8, 2026). Small Molecule PET Tracer Penetrates Brain But Lacks Specificity. Scienmag.

Tags: allosteric modulatorbiodistributionBlood-brain barriercarbon-11evaluationGLP-1RMetabolic disordersPET imagingpreclinicalpreclinical studyradiosynthesisSuzuki-Miyaura coupling
Share12Tweet7Share2ShareShareShare1

Related Posts

Pediatric Solid Tumor CAR-T Therapy Demonstrates Early Activity Alongside Critical Barriers

Pediatric Solid Tumor CAR-T Therapy Demonstrates Early Activity Alongside Critical Barriers

November 17, 2026
Migraine Patients Experience Reduced Anxiety and Depression During CGRP Therapy in UAE Study

Migraine Patients Experience Reduced Anxiety and Depression During CGRP Therapy in UAE Study

November 17, 2026

Animal Morbilliviruses Mirror Genetic Mutations Driving Fatal Human Measles Brain Complications

November 17, 2026

Industrial AI Vision Platform Proves Capable of Identifying Surgical Instruments

November 17, 2026

POPULAR NEWS

  • Vitamin A Deficiency Persists in Congolese Children Despite Long-Term Supplementation Efforts

    Vitamin A Deficiency Persists in Congolese Children Despite Long-Term Supplementation Efforts

    29 shares
    Share 12 Tweet 7
  • Veterinarians Identify Twelve Defences to Improve Medication Safety in Sows

    29 shares
    Share 12 Tweet 7
  • Ascending Aorta Shows Marked Elongation Before Dissection Despite Only Moderate Dilatation

    29 shares
    Share 12 Tweet 7
  • Rural Australian Hospital Study Links Insulin and Polypharmacy to Medication Readmissions

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Migratory Eurasian Curlew Flight Patterns Over North Sea Wind Farm Zones

Read Level Sequencing Exposes Hidden CFTR Splicing Variants Across Global Populations

Pediatric Solid Tumor CAR-T Therapy Demonstrates Early Activity Alongside Critical Barriers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.